Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Amortization of Deferred Charges: 2016-2024

Historic Amortization of Deferred Charges for Kura Oncology (KURA) over the last 7 years, with Dec 2024 value amounting to $523,000.

  • Kura Oncology's Amortization of Deferred Charges rose 5.22% to $141,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $552,000, marking a year-over-year change of. This contributed to the annual value of $523,000 for FY2024, which is 9.64% up from last year.
  • Latest data reveals that Kura Oncology reported Amortization of Deferred Charges of $523,000 as of FY2024, which was up 9.64% from $477,000 recorded in FY2023.
  • In the past 5 years, Kura Oncology's Amortization of Deferred Charges ranged from a high of $523,000 in FY2024 and a low of $73,000 during FY2022.
  • Moreover, its 3-year median value for Amortization of Deferred Charges was $477,000 (2023), whereas its average is $357,667.
  • As far as peak fluctuations go, Kura Oncology's Amortization of Deferred Charges slumped by 81.70% in 2022, and later spiked by 553.42% in 2023.
  • Yearly analysis of 4 years shows Kura Oncology's Amortization of Deferred Charges stood at $399,000 in 2021, then plummeted by 81.70% to $73,000 in 2022, then skyrocketed by 553.42% to $477,000 in 2023, then grew by 9.64% to $523,000 in 2024.